T. Rowe Price Associates
KRYS icon

T. Rowe Price Associates’s Krystal Biotech KRYS Stock Holding History

T. Rowe Price Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125M Sell
485,074
-44,881
-8% -$11.9M 0.01% 569
2025
Q4 		$131M Buy
529,955
+62,897
+13% +$13.2M 0.01% 571
2025
Q3 		$82.5M Buy
467,058
+205,675
+79% +$30.8M 0.01% 667
2025
Q2 		$35.9M Sell
261,383
-149,478
-36% -$22M ﹤0.01% 819
2025
Q1 		$74.1M Sell
410,861
-98,598
-19% -$16.6M 0.01% 612
2024
Q4 		$79.8M Buy
509,459
+71,200
+16% +$12.6M 0.01% 624
2024
Q3 		$79.8M Sell
438,259
-161,886
-27% -$31.2M 0.01% 619
2024
Q2 		$110M Sell
600,145
-58,473
-9% -$9.82M 0.01% 528
2024
Q1 		$117M Buy
658,618
+231,255
+54% +$32.1M 0.01% 513
2023
Q4 		$53M Buy
427,363
+171,157
+67% +$19M 0.01% 695
2023
Q3 		$29.7M Sell
256,206
-68,741
-21% -$8.39M ﹤0.01% 824
2023
Q2 		$38.1M Buy
324,947
+314,337
+2,963% +$32.1M 0.01% 775
2023
Q1 		$850K Buy
10,610
+688
+7% +$54.1K ﹤0.01% 1862
2022
Q4 		$786K Sell
9,922
-272
-3% -$20.2K ﹤0.01% 1903
2022
Q3 		$711K Buy
10,194
+3,218
+46% +$232K ﹤0.01% 1945
2022
Q2 		$458K Sell
6,976
-2,497
-26% -$155K ﹤0.01% 2254
2022
Q1 		$630K Buy
9,473
+1,368
+17% +$85.4K ﹤0.01% 2239
2021
Q4 		$567K Buy
8,105
+3,886
+92% +$226K ﹤0.01% 2326
2021
Q3 		$220K Hold
4,219
– – ﹤0.01% 2689
2021
Q2 		$287K Buy
4,219
+500
+13% +$34.9K ﹤0.01% 2610
2021
Q1 		$287K Buy
+3,719
New +$270K ﹤0.01% 2582
2020
Q4 		– Sell
-482,899
Closed -$20.8M – 2703
2020
Q3 		$20.8M Sell
482,899
-539,516
-53% -$23.4M ﹤0.01% 1148
2020
Q2 		$42.3M Buy
1,022,415
+129,591
+15% +$6.23M 0.01% 904
2020
Q1 		$38.6M Sell
892,824
-157,761
-15% -$8.25M 0.01% 867
2019
Q4 		$58.2M Sell
1,050,585
-25,173
-2% -$1.23M 0.01% 864
2019
Q3 		$37.4M Buy
1,075,758
+148,679
+16% +$6.65M 0.01% 966
2019
Q2 		$37.3M Buy
927,079
+622,959
+205% +$20.4M 0.01% 984
2019
Q1 		$10M Buy
304,120
+600
+0.2% +$14.1K ﹤0.01% 1321
2018
Q4 		$6.31M Buy
+303,520
New +$6.35M ﹤0.01% 1380

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's KRYS Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Krystal Biotech (KRYS) stake by 8.5% in Q1 2026, selling an estimated $11.9M and leaving 485,074 shares worth $125M. The position accounts for 0.01% of the portfolio, ranked #569.

T. Rowe Price Associates first reported a position in KRYS in Q4 2018 and has held it in 29 quarters since. The position peaked at $131M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • T. Rowe Price Associates held 485,074 shares of Krystal Biotech worth $125M as of Q1 2026.
  • T. Rowe Price Associates sold 44,881 Krystal Biotech shares in Q1 2026, an estimated $11.9M.
  • Krystal Biotech made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #569 holding.
  • T. Rowe Price Associates first reported a position in Krystal Biotech in Q4 2018 and has held it in 29 quarters since.
  • T. Rowe Price Associates's Krystal Biotech position peaked at $131M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.